Denosumab biosimilars – useful reports
Posted in Announcement, Biosimilars, Integrated Care, News
Most of you will already be aware that denosumab lost patent exclusivity in November 2025, which has opened the door to a growing range of biosimilars now entering the NHS supply chain. To help you stay informed and explore how these changes may affect local usage and spend, we’ve pulled together a set of useful biosimilar insight reports.
These interactive reports allow you to review uptake trends, cost differences, and product mix within your own Trust and across the wider region. They’re ideal for anyone involved in medicines optimisation, financial planning, or formulary oversight.
‘My Trust’ biosimilar vs originator monthly cost & usage trends
Track how biosimilars are being adopted in your organisation over time*
Trust comparison cost and usage biosimilar vs originator (last 2 months)
Compare uptake across neighbouring or regional Trusts (date range adjustable)*
Trust comparison cost and usage with actual product names
See exactly which products are being used where, with brand‑level detail*
*all links require access to HSCN connection and a Define user account
Read more